

Die Gicht – lästig, aber behandelbar

La goutte – ennuyeuse, mais traitable

Literatur / Références

1. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. *Nat Rev Rheumatol* 2012; 9: 13–23.
2. Roddy E, Doherty M. Epidemiology of gout. *Arthritis Res Ther* 2010; 12: 223.
3. Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. *Nat Rev Rheumatol* 2012; 8: 610–21.
4. Krishnan E, Lessov-Schlaggar CN, Krasnow RE, Swan GE. Nature versus nurture in gout: a twin study. *Am J Med* 2012; 125: 499–504.
5. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. *Lancet* 2004; 363: 1277–81.
6. Richette P, Bardin T. Gout. *Lancet* 2010; 375: 318–28.
7. Caspi D, Lubart E, Graff E, Habot B, Yaron M et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. *Arthritis Rheum* 2000; 43: 103–8.
8. Zhang Y, Chen C, Choi H, Chaisson C, Hunter D et al. Purine-rich foods intake and recurrent gout attacks. *Ann Rheum Dis* 2012; 71: 1448–53.
9. McQueen FM, Chhana A, Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies. *Nat Rev Rheumatol* 2012; 8: 173–81.
10. Pascual E, Batlle-Gualda E, Martínez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. *Ann Intern Med* 1999; 131: 756–9.
11. Stamp LK, Khanna PP, Dalbeth N, Boers M, Maksymowych WP et al. Serum urate in chronic gout – will it be the first validated soluble biomarker in rheumatology? *J Rheumatol* 2011; 38: 1462–6.
12. Urano W, Yamanaka H, Tsutani H, Nakajima H, Matsuda Y et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. *J Rheumatol* 2002; 29: 1950–3.
13. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). *Ann Rheum Dis* 2006; 65: 1301–11.
14. Howard RG, Pillinger MH, Gyftopoulos S, Thiele RG, Swearingen CJ et al. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. *Arthritis Care Res* 2011; 63: 1456–62.
15. Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K et al. Dual energy computed tomography in tophaceous gout. *Ann Rheum Dis* 2009; 68: 1609–12.
16. Glazebrook KN, Guimarães LS, Murthy NS, Black DF, Bongartz T et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. *Radiology* 2011; 261: 516–24.
17. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). *Ann Rheum Dis* 2006; 65: 1312–24.
18. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. *Rheumatology (Oxford)* 2007; 46: 1372–4.
19. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res* 2012; 64: 1431–46.
20. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. *Lancet* 2008; 371: 1854–60.
21. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. *Arthritis Rheum* 2010; 62: 1060–8.
22. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. *N Engl J Med* 2005; 353: 2450–61.
23. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. *Lancet* 2011; 377: 165–77.
24. Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. *Curr Opin Rheumatol* 2010; 22: 165–72.
25. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. *N Engl J Med* 2004; 350: 1093–103.

26. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. *BMJ* 2008; 336: 309–12.
27. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. *Arthritis Rheum* 2007; 56: 2049–55.
28. Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. *BMJ* 2012; 344: d8190.
29. Würzner G, Gerster JC, Chioloro A, Maillard M, Fallab-Stubi CL et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. *J Hypertens* 2001; 19: 1855–60.
30. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. *Arthritis Care Res.* 2012; 64: 1447–61.
31. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. *Am J Med* 1984; 76: 47–56.
32. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. *J Rheumatol* 2006; 33: 1646–50.
33. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. *Arthritis Rheum* 2012; 64: 2529–36.
34. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. *Arthritis Rheum* 2011; 63: 412–21.
35. Keenan RT. Safety of urate-lowering therapies: managing the risks to gain the benefits. *Rheum Dis Clin North Am* 2012; 38: 663–80.
36. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. *Rheumatology (Oxford)* 2003; 42: 321–5.
37. Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. *Arch Intern Med* 2009; 169: 502–7.
38. Garay RP, El-Gewely MR, Labaune JP, Richette P. Therapeutic perspectives on uricases for gout. *Joint Bone Spine* 2012; 79: 237–42.
39. Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F et al. Gout: why is this curable disease so seldom cured? *Ann Rheum Dis* 2012; 71: 1765–70.
40. Reach G. Treatment adherence in patients with gout. *Joint Bone Spine* 2011; 78: 456–9.
41. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH et al. Long-term cardiovascular mortality among middle-aged men with gout. *Arch Intern Med* 2008; 168: 1104–10.
42. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. *Rheumatology (Oxford)* 2013; 52: 34–44.